Search

Your search keyword '"Brown, Jacqueline T"' showing total 147 results
Start Over Author "Brown, Jacqueline T"
147 results on '"Brown, Jacqueline T"'

1. Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy

Author

Nicaise, Edouard H., Schmeusser, Benjamin N., Ali, Adil, Midenberg, Eric, Palacios, Arnold R., Hartsoe, Blaise, Kearns, Ethan, Ambadi, Sriram, Patil, Dattatraya H., Joshi, Shreyas S., Narayan, Vikram M., Psutka, Sarah P., Nazha, Bassel, Brown, Jacqueline T., Ogan, Kenneth, Bilen, Mehmet A., and Master, Viraj A.

Published
2024
Full Text
View/download PDF

4. Clinical outcome differences based on gender in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).

Author

Choi, Yujin, primary, Goswamy, Rohit Vivek, additional, Wei, Mengting, additional, Liu, Yuan, additional, Yildirim, Ahmet, additional, Brown, Jacqueline T., additional, Nazha, Bassel, additional, Martini, Dylan J., additional, Hartman, Caitlin, additional, McClintock, Greta Russler, additional, Zhuang, Tony, additional, Kissick, Haydn, additional, Harris, Wayne B., additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2024
Full Text
View/download PDF

5. Association of body mass index (BMI) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).

Author

Goswamy, Rohit Vivek, primary, Yildirim, Ahmet, additional, Choi, Yujin, additional, Wei, Mengting, additional, Liu, Yuan, additional, Brown, Jacqueline T, additional, Nazha, Bassel, additional, Martini, Dylan J., additional, Hartman, Caitlin, additional, McClintock, Greta Russler, additional, Zhuang, Tony, additional, Kissick, Haydn, additional, Harris, Wayne Bernard, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2024
Full Text
View/download PDF

6. Association of race with clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs).

Author

Choi, Yujin, primary, Yildirim, Ahmet, additional, Wei, Mengting, additional, Liu, Yuan, additional, Goswamy, Rohit Vivek, additional, Brown, Jacqueline T., additional, Nazha, Bassel, additional, Martini, Dylan J., additional, Hartman, Caitlin, additional, McClintock, Greta Russler, additional, Zhuang, Tony, additional, Kissick, Haydn, additional, Harris, Wayne B., additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2024
Full Text
View/download PDF

8. Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).

Author

Goswamy, Rohit Vivek, primary, Yildirim, Ahmet, additional, Wei, Mengting, additional, Liu, Yuan, additional, Choi, Yujin, additional, Brown, Jacqueline T, additional, Nazha, Bassel, additional, Master, Viraj A., additional, Martini, Dylan J., additional, Carthon, Bradley Curtis, additional, Harris, Wayne Bernard, additional, Kucuk, Omer, additional, Kissick, Haydn, additional, Hartman, Caitlin, additional, McClintock, Greta Russler, additional, Vo, Baohan Thi, additional, Jansen, Caroline Stewart, additional, Zhuang, Tony, additional, and Bilen, Mehmet Asim, additional

Published
2024
Full Text
View/download PDF

12. PD‐L1 and nectin‐4 expression and genomic characterization of bladder cancer with divergent differentiation.

Author

Martini, Dylan J., Case, Katherine B., Gratz, Derrik, Pellegrini, Kathryn, Beagle, Elizabeth, Schneider, Thomas, Dababneh, Melad, Nazha, Bassel, Brown, Jacqueline T., Joshi, Shreyas S., Narayan, Vikram M., Ogan, Kenneth, Master, Viraj A., Carthon, Bradley C., Kucuk, Omer, Harik, Lara R., and Bilen, Mehmet Asim

Subjects
GENE expression, GENOMICS, IMMUNE checkpoint inhibitors, RNA sequencing, INDIVIDUALIZED medicine
Abstract

Background: Bladder cancer with divergent differentiation (BCDD) comprises a heterogenous group of tumors with a poor prognosis, and differential expression of nectin‐4 and programmed death ligand‐1 (PD‐L1) has been reported in BCDD. Importantly, nectin‐4 expression in bladder cancer is associated with response to enfortumab vedotin, and PD‐L1 expression is associated with responses to immune checkpoint inhibitors (ICIs). Methods: The authors conducted a retrospective review identifying 117 patients with advanced or metastatic BCDD who were treated at Winship Cancer Institute from 2011 to 2021. They performed immunohistochemistry staining for nectin‐4 and PD‐L1 expression by histologic subtype as well as genomic analysis of these patients, including RNA sequencing, whole‐exome sequencing, and fusion detection analysis as well as a subgroup genomic analysis of patients with BCDD who received ICIs. Results: The results indicated that nectin‐4 expression was highest in the groups who had the squamous and plasmacytoid subtypes, whereas the group that had the sarcomatoid subtype (70.8%) had the highest proportion of PD‐L1–positive patients. Genomic analysis yielded several key findings, including a 50% RB1 mutation rate in patients who had small cell BCDD, targetable PIK3CA mutations across multiple subtypes of BCDD, and significantly higher expression of TEC in responders to ICIs. Conclusions: In this study, the authors identified clinically relevant data on nectin‐4 and PD‐L1 expression in patients with rare bladder tumors. They also identified several novel findings in the genomic analysis that highlight the role of precision medicine in this population of patients. Larger, prospective studies are needed to validate these hypothesis‐generating data. In this study, the authors performed a retrospective analysis focused on the histologic and genomic characterization of bladder cancer with divergent differentiation. The results indicated that nectin‐4 expression was highest in patients with squamous and plasmacytoid differentiation, whereas patients who had sarcomatoid differentiation (70.8%) had the highest proportion of programmed death ligand‐1–positive disease, and several novel findings were identified in the genomic analysis that have potential clinical implications for these patients with rare tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. MP10-16 LINEAR MUSCLE SEGMENTATION FOR METASTATIC RENAL CELL CARCINOMA: CHANGES IN CLINIC-FRIENDLY ESTIMATION PREDICT SURVIVAL IN PATIENTS FOLLOWING CYTOREDUCTIVE NEPHRECTOMY

Author

Nicaise, Edouard H.*, primary, Schmeusser, Benjamin N., additional, Ali, Adil, additional, Midenberg, Eric, additional, Palacios, Arnold R., additional, Kearns, Ethan, additional, Ambadi, Sriram, additional, Psutka, Sarah P., additional, Nazha, Bassel, additional, Brown, Jacqueline T., additional, Ogan, Kenneth, additional, Bilen, Mehmet A., additional, and Master, Viraj A., additional

Published
2024
Full Text
View/download PDF

16. The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression

Author

Hadadi, Agreen, primary, Krause, Harris B., additional, Elliott, Andrew, additional, Brown, Jacqueline T., additional, Nazha, Bassel, additional, Harik, Lara R., additional, Carthon, Bradley C., additional, Miron, Benjamin, additional, Nabhan, Chadi, additional, Barata, Pedro C., additional, Saleh, Mohamed, additional, Yang, Yuanquan, additional, McKay, Rana R., additional, and Bilen, Mehmet A., additional

Published
2023
Full Text
View/download PDF

17. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers

Author

Nazha, Bassel, primary, Zhuang, Tony, additional, Wu, Sharon, additional, Brown, Jacqueline T., additional, Magee, Daniel, additional, Carthon, Bradley C., additional, Kucuk, Omer, additional, Nabhan, Chadi, additional, Barata, Pedro C., additional, Heath, Elisabeth I., additional, Ryan, Charles J., additional, McKay, Rana R., additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2023
Full Text
View/download PDF

18. Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors

Author

Sanda, Gregory E, primary, Shabto, Julie M, additional, Goyal, Subir, additional, Liu, Yuan, additional, Martini, Dylan J, additional, Nazha, Bassel, additional, Brown, Jacqueline T, additional, Yantorni, Lauren B, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Joshi, Shreyas S, additional, Narayan, Vikram M, additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Master, Viraj A, additional, Carthon, Bradley C, additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2023
Full Text
View/download PDF

21. Linear muscle segmentation for metastatic renal cell carcinoma.

Author

Nicaise, Edouard, Schmeusser, Benjamin, Ali, Adil, Midenberg, Eric, Palacios, Arnold Raul, Kearns, Ethan, Ambadi, Sriram, Patil, Dattatraya H., Joshi, Shreyas S., Narayan, Vikram M, Psutka, Sarah P., Nazha, Bassel, Brown, Jacqueline T, Ogan, Kenneth, Bilen, Mehmet Asim, and Master, Viraj A.

Published
2024
Full Text
View/download PDF

23. Association of baseline inflammatory biomarkers with outcomes in penile squamous cell carcinoma (pSCC) treated with immune checkpoint inhibitors (ICI).

Author

Zhuang, Tony, primary, Goyal, Subir, additional, Brown, Jacqueline T, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, McClintock, Greta Russler, additional, Yantorni, Lauren Beth, additional, Bilen, Mehmet Asim, additional, Master, Viraj A., additional, and Nazha, Bassel, additional

Published
2023
Full Text
View/download PDF

24. Exploration of immunosuppressive features of the tumor microenvironment within hepatic and non-hepatic tumors of urothelial origin.

Author

Brown, Jacqueline T, primary, Elliott, Andrew, additional, Walker, Phillip, additional, Xiu, Joanne, additional, Nazha, Bassel, additional, Stewart, Tyler F., additional, Gulati, Shuchi, additional, Nandagopal, Lakshminarayanan, additional, Goldman, Jamie, additional, Kucuk, Omer, additional, Carthon, Bradley Curtis, additional, Barata, Pedro C., additional, Hoon, Dave S. B., additional, McKay, Rana R., additional, Agarwal, Neeraj, additional, Nabhan, Chadi, additional, Korn, W. Michael, additional, and Bilen, Mehmet Asim, additional

Published
2023
Full Text
View/download PDF

25. Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report

Author

Zhuang, Tony Zibo, primary, Harik, Lara, additional, Force, Seth, additional, Hadadi, Agreen, additional, Bilen, Mehmet Asim, additional, Brown, Jacqueline T., additional, Carthon, Bradley C., additional, Goldman, Jamie, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Nazha, Bassel, additional

Published
2022
Full Text
View/download PDF

26. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Author

Zhuang, Tony Z, primary, Ravindranathan, Deepak, additional, Liu, Yuan, additional, Martini, Dylan J, additional, Brown, Jacqueline T, additional, Nazha, Bassel, additional, Russler, Greta, additional, Yantorni, Lauren B, additional, Caulfield, Sarah, additional, Carthon, Bradley C, additional, Kucuk, Omer, additional, Master, Viraj A, additional, and Bilen, Mehmet Asim, additional

Published
2022
Full Text
View/download PDF

27. Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience

Author

Martini, Dylan J., primary, Olsen, T. Anders, additional, Goyal, Subir, additional, Liu, Yuan, additional, Evans, Sean T., additional, Hitron, Emilie Elise, additional, Russler, Greta Anne, additional, Yantorni, Lauren, additional, Caulfield, Sarah, additional, Brown, Jacqueline T., additional, Goldman, Jamie M., additional, Nazha, Bassel, additional, Carthon, Bradley C., additional, Harris, Wayne B., additional, Kucuk, Omer, additional, Master, Viraj A, additional, and Bilen, Mehmet Asim, additional

Published
2022
Full Text
View/download PDF

29. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.

Author

Zhuang, Tony Z, Ravindranathan, Deepak, Liu, Yuan, Martini, Dylan J, Brown, Jacqueline T, Nazha, Bassel, Russler, Greta, Yantorni, Lauren B, Caulfield, Sarah, Carthon, Bradley C, Kucuk, Omer, Master, Viraj A, and Bilen, Mehmet Asim

Subjects
RENAL cell carcinoma, EOSINOPHILS, STATISTICS, IMMUNE checkpoint inhibitors, PREDICTIVE tests, CONFIDENCE intervals, MULTIVARIATE analysis, METASTASIS, RETROSPECTIVE studies, ACQUISITION of data, NEUTROPHILS, TREATMENT effectiveness, MEDICAL records, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, RESEARCH funding, TUMOR markers, PROGRESSION-free survival, OVERALL survival
Abstract

Background Biomarkers have the potential to guide treatment selection and clinical care in metastatic renal cell carcinoma (mRCC) in an expanding treatment landscape. We report baseline neutrophil-to-eosinophil ratios (NER) in patients with mRCC treated with immune checkpoint inhibitors (CPIs) and their association with clinical outcomes. Methods We conducted a retrospective review of patients with mRCC treated with CPIs at Winship Cancer Institute from 2015 to 2020 in the United States of America (USA). Demographics, disease characteristics, and laboratory data, including complete blood counts (CBC) were described at the initiation of CPIs. Clinical outcomes were measured as overall survival (OS), progression-free survival (PFS), and clinical benefit (CB) associated with baseline lab values. Results A total of 184 patients were included with a median follow-up time of 25.4 months. Patients with baseline NER were categorized into high or low subgroups; high group was defined as NER >49.2 and low group was defined as NER <49.2 with 25% of patients in the high NER group. Univariate analyses (UVA) and multivariable analyses (MVA) identified decreased overall survival (OS) associated with elevated NER. In MVA, patients with a high baseline NER group had a hazard ratio (HR) of 1.68 (95%CI, 1.01-2.82, P =.048) for OS; however, there was no significant difference between groups for PFS. Clinical benefit was seen in 47.3% of patients with low baseline NER and 40% with high NER. Conclusions We conclude that elevated baseline NER may be associated with worse clinical outcomes in mRCC. Although results require further validation, NER is a feasible biomarker in patients with CPI-treated mRCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma

Author

Nazha, Bassel, primary, Zhuang, Tony Z, additional, Dada, Hiba I, additional, Drusbosky, Leylah M, additional, Brown, Jacqueline T, additional, Ravindranathan, Deepak, additional, Carthon, Bradley C, additional, Kucuk, Omer, additional, Goldman, Jamie, additional, Master, Viraj A, additional, and Bilen, Mehmet Asim, additional

Published
2022
Full Text
View/download PDF

32. Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).

Author

Sanda, Gregory E., primary, Shabto, Julie M., additional, Goyal, Subir, additional, Liu, Yuan, additional, Martini, Dylan J., additional, Nazha, Bassel, additional, Brown, Jacqueline T, additional, Yantorni, Lauren Beth, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Joshi, Shreyas S., additional, Narayan, Vikram M., additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Master, Viraj A., additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2022
Full Text
View/download PDF

33. Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.

Author

Nazha, Bassel, primary, Wu, Sharon, additional, Brown, Jacqueline T, additional, Magee, Daniel, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Korn, W. Michael, additional, Barata, Pedro C., additional, Heath, Elisabeth I., additional, Ryan, Charles J., additional, McKay, Rana R., additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2022
Full Text
View/download PDF

34. Phase 2 study of neoadjuvant cabozantinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma.

Author

Bilen, Mehmet Asim, primary, Liu, Yuan, additional, Nazha, Bassel, additional, Brown, Jacqueline T, additional, Osunkoya, Adeboya O., additional, Williams, Sierra, additional, Session, Wilena, additional, Yantorni, Lauren Beth, additional, Russler, Greta, additional, Caulfield, Sarah, additional, Joshi, Shreyas S., additional, Narayan, Vikram M., additional, Filson, Christopher Paul, additional, Ogan, Kenneth, additional, Kucuk, Omer, additional, Carthon, Bradley Curtis, additional, Kissick, Haydn, additional, and Master, Viraj A., additional

Published
2022
Full Text
View/download PDF

35. Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology.

Author

Case, Katherine, primary, Martini, Dylan J., additional, Dababneh, Melad, additional, Nazha, Bassel, additional, Brown, Jacqueline T, additional, Joshi, Shreyas S., additional, Narayan, Vikram M., additional, Ogan, Kenneth, additional, Master, Viraj A., additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Harik, Lara, additional, and Bilen, Mehmet Asim, additional

Published
2022
Full Text
View/download PDF

37. The prognostic role of sarcopenia and albumin in locally advanced renal cell carcinoma with IVC tumor thrombus.

Author

Midenberg, Eric, primary, Patil, Dattatraya H, additional, Medline, Alexandra, additional, Higgins, Michelle, additional, Williams, Milton, additional, Nazha, Bassel, additional, Brown, Jacqueline T, additional, Ogan, Kenneth, additional, Psutka, Sarah P., additional, Bilen, Mehmet Asim, additional, and Master, Viraj A., additional

Published
2022
Full Text
View/download PDF

39. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors

Author

Martini, Dylan J., primary, Shabto, Julie M., additional, Goyal, Subir, additional, Liu, Yuan, additional, Olsen, T. Anders, additional, Evans, Sean T., additional, Magod, Benjamin L., additional, Ravindranathan, Deepak, additional, Brown, Jacqueline T., additional, Yantorni, Lauren, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Goldman, Jamie M., additional, Nazha, Bassel, additional, Joshi, Shreyas Subhash, additional, Kissick, Haydn T., additional, Ogan, Kenneth E., additional, Harris, Wayne B., additional, Kucuk, Omer, additional, Carthon, Bradley C., additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

40. Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors

Author

Martini, Dylan J., primary, Olsen, T. Anders, additional, Goyal, Subir, additional, Liu, Yuan, additional, Evans, Sean T., additional, Magod, Benjamin, additional, Brown, Jacqueline T., additional, Yantorni, Lauren, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Goldman, Jamie M., additional, Nazha, Bassel, additional, Kissick, Haydn T., additional, Harris, Wayne B., additional, Kucuk, Omer, additional, Carthon, Bradley C., additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

41. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Author

Martini, Dylan J., primary, Goyal, Subir, additional, Liu, Yuan, additional, Evans, Sean T., additional, Olsen, T. Anders, additional, Case, Katherine, additional, Magod, Benjamin L., additional, Brown, Jacqueline T., additional, Yantorni, Lauren, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Goldman, Jamie M., additional, Nazha, Bassel, additional, Harris, Wayne B., additional, Kissick, Haydn T., additional, Master, Viraj A., additional, Kucuk, Omer, additional, Carthon, Bradley C., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

42. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors

Author

Brown, Jacqueline T, primary, Liu, Yuan, additional, Shabto, Julie M, additional, Martini, Dylan, additional, Ravindranathan, Deepak, additional, Hitron, Emilie Elise, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Yantorni, Lauren, additional, Joshi, Shreyas Subhash, additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Nazha, Bassel, additional, Carthon, Bradley C, additional, Kucuk, Omer, additional, Harris, Wayne B, additional, Master, Viraj A, additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

43. Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade

Author

Olsen, T. Anders, primary, Martini, Dylan J., additional, Goyal, Subir, additional, Liu, Yuan, additional, Evans, Sean T., additional, Magod, Benjamin, additional, Brown, Jacqueline T., additional, Yantorni, Lauren, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Goldman, Jamie M., additional, Harris, Wayne B., additional, Kucuk, Omer, additional, Carthon, Bradley C., additional, Master, Viraj A., additional, Nazha, Bassel, additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

45. Baseline neutrophil-to-eosinophil ratio (NER) and its association with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).

Author

Ravindranathan, Deepak, primary, Liu, Yuan, additional, Martini, Dylan J., additional, Brown, Jacqueline T, additional, Nazha, Bassel, additional, Russler, Greta, additional, Yantorni, Lauren Beth, additional, Caulfield, Sarah, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

46. Baseline modified Glasgow prognostic score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI).

Author

Brown, Jacqueline T, primary, Liu, Yuan, additional, Martini, Dylan J., additional, Shabto, Julie M., additional, Russler, Greta, additional, Caulfield, Sarah, additional, Yantorni, Lauren Beth, additional, Joshi, Shreyas S., additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Nazha, Bassel, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Harris, Wayne, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

48. Clinical outcomes in metastatic renal cell carcinoma (mRCC) treated with combination of nivolumab and cabozantinib (nivo-cabo) in the salvage setting.

Author

Ravindranathan, Deepak, primary, Liu, Yuan, additional, Martini, Dylan J., additional, Nazha, Bassel, additional, Brown, Jacqueline T, additional, Russler, Greta, additional, Yantorni, Lauren Beth, additional, Caulfield, Sarah, additional, Master, Viraj A., additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

49. Association of basophil to lymphocyte ratio (BLR) with clinical outcomes in metastatic hormone sensitive prostate cancer.

Author

Smith, Katherine Emilie Rhoades, primary, Wan, Limeng, additional, Liu, Yuan, additional, Brown, Jacqueline T, additional, Russler, Greta, additional, Yantorni, Lauren Beth, additional, Caulfield, Sarah, additional, Carthon, Bradley Curtis, additional, Kucuk, Omer, additional, Nazha, Bassel, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

50. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors

Author

Brown, Jacqueline T., primary, Liu, Yuan, additional, Shabto, Julie M., additional, Martini, Dylan J., additional, Ravindranathan, Deepak, additional, Hitron, Emilie Elise, additional, Russler, Greta Anne, additional, Caulfield, Sarah, additional, Yantorni, Lauren Beth, additional, Joshi, Shreyas S., additional, Kissick, Haydn, additional, Ogan, Kenneth, additional, Harris, Wayne B., additional, Carthon, Bradley C., additional, Kucuk, Omer, additional, Master, Viraj A., additional, and Bilen, Mehmet Asim, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results